share_log

BioSyent Launches "Menopauseinformation.ca" on World Menopause Day

BioSyent Launches "Menopauseinformation.ca" on World Menopause Day

BioSyent 在世界更年期日推出 “menopauseInformation.ca”
GlobeNewswire ·  2023/10/18 08:00

MISSISSAUGA, Ontario, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce the launch of menopauseinformation.ca, a comprehensive online platform designed to empower peri-menopausal and menopausal women across Canada.

安大略省密西沙加,2023年10月18日(GLOBE NEWSWIRE)——BioSyent Inc.(“BioSyent”,多伦多证券交易所风险投资代码:RX)很高兴地宣布推出 更年期信息.ca,一个全面的在线平台,旨在增强加拿大各地围绝经期和更年期女性的能力。

Menopause is a natural transition that every woman experiences, and understanding this transition is crucial for a smoother journey. The menopauseinformation.ca website aims to provide vital information and resources to help women navigate through this transition with confidence. By being informed, women can engage in more effective discussions with their healthcare providers, leading to better-managed menopause experiences.

更年期是每个女性都会经历的自然过渡,了解这种过渡对于更顺畅的旅程至关重要。的 更年期信息.ca 网站旨在提供重要的信息和资源,帮助女性自信地度过这一过渡。通过了解情况,女性可以与医疗保健提供者进行更有效的讨论,从而更好地管理更年期经历。

This platform offers a wealth of up-to-date information including expert insights from trusted Canadian menopause doctors, frequently asked questions, and engaging blogs. BioSyent is collaborating with these reputable experts to demystify the biological and emotional changes occurring during menopause, ensuring women have the knowledge and support they need to make informed decisions about their health.

该平台提供了大量最新信息,包括来自值得信赖的加拿大更年期医生的专家见解、常见问题和引人入胜的博客。BioSyent正在与这些著名的专家合作,揭开更年期期间发生的生物学和情感变化的神秘面纱,确保女性获得所需的知识和支持,以便就自己的健康做出明智的决定。

"Menopause is a significant phase in a woman's life, and we recognize the importance of providing up-to-date and accessible information to support women in Canada," said René Goehrum, President and CEO of BioSyent. "We are committed to empowering women to take charge of their health by understanding menopause and engaging with their healthcare providers with confidence."

BioSyent总裁兼首席执行官René Goehrum表示:“更年期是女性生活中的一个重要阶段,我们认识到提供最新和可获得的信息以支持加拿大女性的重要性。”“我们致力于通过了解更年期并充满信心地与医疗保健提供者接触,增强女性掌控健康的能力。”

"On behalf of the board of directors of the Canadian Menopause Society (CMS), we are happy to endorse this educational initiative on menopause," said Dr. Wendy Wolfman, President of the CMS and Dr. Nese Yuksel, President elect of the CMS. "This series of videos will help inform individuals about the common symptoms of menopause, long term consequences and management approaches. The Canadian Menopause Society is committed to advancing the health of individuals at and beyond the menopause transition through educational programs and practice based initiatives."

加拿大更年期协会(CMS)主席温迪·沃尔夫曼博士和加拿大更年期协会(CMS)当选主席内斯·尤克塞尔博士说:“我们很高兴代表加拿大更年期协会(CMS)董事会支持这项关于更年期的教育计划。”“这一系列的视频将帮助人们了解更年期的常见症状、长期后果和管理方法。加拿大更年期协会致力于通过教育计划和基于实践的举措来促进更年期过渡期及以后的个人健康。”

For more information or to explore the menopauseinformation.ca website, please visit:
or contact:
Email: info@menopauseinformation.ca
Phone: 905-206-0013

欲了解更多信息或浏览 更年期信息.ca 网站,请访问:
或者联系:
电子邮件:info@menopauseinformation.ca
电话:905-206-0013

About BioSyent Inc.

关于 BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

BioSyent在多伦多证券交易所风险投资交易所上市,交易代码为 “RX”,是一家以增长为导向的盈利型专业制药公司,专注于许可或收购创新药物和其他医疗保健产品,这些产品已成功开发,安全有效,在改善患者生活方面有着良好的记录。BioSyent通过其社区、专业和国际业务部门销售其产品,为治疗这些患者的医疗保健专业人员提供支持。

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

本新闻稿可能包含前瞻性的信息或陈述。此处的内容代表我们截至发布之日的判断,并且存在风险和不确定性,这些风险和不确定性可能会导致实际结果或结果与前瞻性信息或陈述存在重大差异。潜在风险可能包括但不限于与临床试验、产品开发、未来收入、运营、盈利能力和获得监管部门批准相关的风险。

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

多伦多证券交易所风险交易所及其监管服务提供商(该术语在多伦多证券交易所风险交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发